The Timing Hypothesis remains a valid explanation of differential cardioprotective effects of menopausal hormone treatment

Menopause

Volumn 18, Issue 2, 2011, Pages 230-236

  Choi, Seung Do ^a,b   Steinberg, Emma M ^b   Lee, Hae Hyeog ^a   Naftolin, Frederick ^b  

^a Soonchunhyang University   (South Korea)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Menopausal hormone treatment; Timing Hypothesis; Women's Health Initiative

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTERIAL WALL THICKNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHRONOTHERAPY; CORONARY ARTERY OBSTRUCTION; ENDOTHELIUM CELL; HEART PROTECTION; HORMONAL THERAPY; HORMONE ACTION; HUMAN; MEDICAL LITERATURE; MENOPAUSAL SYNDROME; MENOPAUSE; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VASODILATATION;

CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79951580916     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181e97344     Document Type: Review

References (83)

1. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and heart disease. Epidemiology 2008;19:766-779.
2. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613. (Pubitemid 28502636)
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333. (Pubitemid 34761611)
4. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534. (Pubitemid 36951364)
5. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712. (Pubitemid 38489892)
6. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and risk of cardiovascular disease. N Engl J Med 1996; 335:453-461. (Pubitemid 26269944)
7. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006;15:35-44. (Pubitemid 43192860)
8. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002;53:605-619. (Pubitemid 34175253)
9. Dubey RK, Imthurn B, Barton M, Jackson EK. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res 2005;66:295-306. (Pubitemid 40471044)
10. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of post-menopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009;170:12-23.
11. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
12. Langer RD. Hormone replacement and the prevention of cardiovascular disease. Am J Cardiol 2002;89:36-46.
13. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72. (Pubitemid 28279924)
14. Tan O, Harman SM, Naftolin F. What can we learn from design faults in the Women's Health Initiative randomized clinical trial? Bull N.Y. Univ Hosp Jt Dis 2009;67:226-229.
15. Toth PP. Subclinical atherosclerosis: what it is, what it means and what we can do about it. Int J Clin Prac 2008;62:1246-1254. (Pubitemid 351994084)
16. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109.
17. Schneider HPG, Naftolin F. Climacteric Medicine: Where Do We Go? London; New York: Taylor & Francis, 2005:xiii, 236.
18. Harman SM, Naftolin F, Brinton EA, Judelson DR. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann N Y Acad Sci 2005;1052:43-56. (Pubitemid 41338957)
19. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-650. (Pubitemid 36204960)
20. Barrett-Connor E. Sex differences in coronary heart disease: why are women so superior? The 1995 Ancel Keys Lecture. Circulation 1997;95: 252-264. (Pubitemid 27029969)
21. Isles CG, Hole DJ, Hawthorne VM, Lever AF. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men. Lancet 1992;339:702-706.
22. Tracy RE. Sex difference in coronary disease: two opposing views. J Chronic Dis 1996;19:1245-1251.
23. Maxwell SR. Women and heart disease. Basic Res Cardiol 1998;93:79-84. (Pubitemid 28498136)
24. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-1110. (Pubitemid 17052498)
25. Roano GM, Fini M. Postmenopausal women and cardiovascular risk: impact of hormone replacement therapy. Cardiol Rev 2002;10:51-60. (Pubitemid 34130770)
26. Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999;159:1061-1066. (Pubitemid 29230857)
27. Jacobsen BK, Nilssen S, Heuch I, Kvale G. Does age at natural menopause affect mortality from ischemic heart disease? J Clin Epidemiol 1997;50:475-479. (Pubitemid 27223277)
28. Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger post-menopausal women. Am J Med 2009;122:1016-1022.
29. Kitagawa K, Hougaku H, Yamagami H, et al. Carotid intima-media thickness and risk of cardiovascular events in high-risk patients. Results of the Osaka Follow-Up Study for Carotid Atherosclerosis 2 (OSACA2 Study). Cerebrovasc Dis 2007;24:35-42.
30. Nagai Y, Metter J, Earley CJ, et al. Increased carotid artery intimal-medial thickness in asymptomatic older subjects with exercise-induced myocardial ischemia. Circulation 1998;98:1504-1509. (Pubitemid 28481666)
31. Mack WJ, Slater CC, Xiang M, Shoupe D, Lobo RA, Hodis HN. Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertil Steril 2004;82:391-397. (Pubitemid 39092040)
32. Ge Q, Tian Q, Tseng H, Naftolin F. Development of low-dose reproductive hormone therapies in China. Gynecol Endocrinol 2006;22: 636-645. (Pubitemid 44915730)
33. McGrath BP, Liang YL, Teede H, Shiel LM, Cameron JD, Dart A. Age-related deterioration in arterial structure and function in postmenopausal women. Impact of hormone replacement therapy. Arterioscler Thromb Vasc Biol 1998;18:1149-1156. (Pubitemid 28323600)
34. Burke AP, Farb A, Malcom G, Virmani R. Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis. Am Heart J 2001;141:58-62.
35. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998;83:72-76.
36. Williams JK, Anthony MS, Honore EK, et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 1995;15: 827-836.
37. Stevenson JC. Consultant physician and reader in metabolic medicine. HRT and cardiovascular disease. Best Pract Res Clin Obstet Gynaecol 2009;23:109-120.
38. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-953. (Pubitemid 33131615)
39. Hodis HN, Mack WJ, Azen SP, et al. Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535-545. (Pubitemid 36951365)
40. Naftolin F, Taylor HS, Karas R, et al. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004;81:1498-1501. (Pubitemid 38748989)
41. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-1587. (Pubitemid 40807497)
42. Mendelsohn ME, Karas RH. Protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811. (Pubitemid 29266405)
43. Diano S, Horvath TL, Mor G, et al. Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects. Menopause 1999;6:21-28. (Pubitemid 29131755)
44. Mendelsohn ME, Karas RH. Estrogen and the blood vessel wall. Curr Opin Cardiol 1994;9:619-626. (Pubitemid 24267789)
45. Simoncini T, Scorticati C, Mannella P, et al. Estrogen receptor > interacts with G>13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol Endocrinol 2006;20:1756-1771. (Pubitemid 44148082)
46. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J 1996;10:615-624. (Pubitemid 26141172)
47. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
48. Shwaery GT, Vita JA, Keaney JF Jr. Antioxidant protection of LDL by physiological concentrations of 17A-estradiol: requirement for estradiol modification. Circulation 1997;95:1378-1385. (Pubitemid 27142793)
49. Santanam N, Shern-Brewer R, McClatchey R, et al. Estradiol as an antioxidant: incompatible with its physiological concentrations and function. J Lipid Res 1998;39:2111-2118. (Pubitemid 28523116)
50. Nabulsi AA, Folsom AR, White A, et al. Association of hormone replacement therapy with various cardiovascular risk factors in postmeno-pausal women. N Engl J Med 1993;328:1069-1075. (Pubitemid 23097795)
51. The Writing Group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a one-year, double-blind, placebo-controlled study. Thromb Haemost 1996;75:476-480.
52. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997;336: 683-690. (Pubitemid 27102682)
53. Hemelaar M, Kenemans P, Hack CE, Klipping C, van der Mooren MJ. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial. Menopause 2008;15:248-255. (Pubitemid 351354984)
54. Moncada S, Higgs A. The L-arginineYnitric oxide pathway. N Engl J Med 1993;329:2002-2012.
55. White RE, Darkow DJ, Lang JLF. Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ Res 1995;77:936-942.
56. + channels. Circ Res 1996;79:1024-1030. (Pubitemid 26359243)
57. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994;91:5212-5216. (Pubitemid 24177823)
58. Binko J, Majewski H. 17A-Estradiol reduces vasoconstriction in endothelium-denuded rat aortas through inducible NOS. Am J Physiol 1998;274:853-859.
59. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 1994;267:C1405-C1413.
60. Kolodgie FD, Jacob A, Wilson PS, et al. Estradiol attenuates directed migration of vascular smooth muscle cells in vitro. Am J Pathol 1996;148: 969-976. (Pubitemid 126660688)
61. Bhalla RC, Toth KF, Bhatty RA, Thompson LP, Sharma RV. Estrogen reduces proliferation and agonist-induced calcium increase in coronary artery smooth muscle cells. Am J Physiol 1997;272:1996-2003.
62. Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994;89: 1943-1950. (Pubitemid 24142767)
63. Venkov CD, Rankin AB, Vaughan DE. Identification of authentic estrogen receptor in cultured endothelial cells: a potential mechanism for steroid hormone regulation of endothelial function. Circulation 1996;94: 727-733. (Pubitemid 26289229)
64. Kim-Schulze S, McGowan KA, Hubchak SC, et al. Expression of an estrogen receptor by human coronary artery and umbilical vein endo-thelial cells. Circulation 1996;94:1402-1407. (Pubitemid 26307272)
65. Kuiper GGJM, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors > and A. Endocrinology 1997;138:863-870. (Pubitemid 27089735)
66. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994;89:1501-1510. (Pubitemid 24114224)
67. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321:209-213. (Pubitemid 16016411)
68. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999;43:985-991. (Pubitemid 29413198)
69. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-1775.
70. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477. (Pubitemid 46556472)
71. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005;162:404-414. (Pubitemid 41191425)
72. Scarabin PY, Oger E, Plu-Bureau G, et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous throm-boembolism risk. Lancet 2003;362:428-432. (Pubitemid 36999704)
73. Canonico M, Oger E, Plu-Bureau G, et al. Estrogen and Thromboem-bolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-845. (Pubitemid 46294724)
74. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:307-308.
75. Espie M, Daures JP, Chevallier T, Mares P, Micheletti MC, De Reilhac P. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. Gynecol Endocrinol 2007;23:391-397. (Pubitemid 47301195)
76. Banks E, Canfell K. Invited commentary: hormone therapy risks and benefitsVthe Women's Health Initiative findings and the postmenopausal estrogen Timing Hypothesis. Am J Epidemiol 2009;170:24-28.
77. Verkooijen HM, Bouchardy C, Vinh-Hung V, Rapiti E, Hartman M. The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence. Maturitas 2009;64:80-85.
78. Vankrunkelsven P, Kellen E, Lousbergh D, et al. Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat 2009;118:425-432.
79. Usher C, Teeling M, Bennett K, Feely J. Effect of clinical trial publicity on HRT prescribing in Ireland. Eur J Clin Pharmacol 2006;62:307-310.
80. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005;118:64-73.
81. Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791-804. (Pubitemid 38951954)
82. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363-366.
83. Harman SM, Brinton EA, Cedars M, et al. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3-12. (Pubitemid 40675116)